Nephrology News

ATLANTA — A remote, team-based approach with immediate initiation of necessary medications improved guideline-directed medical therapy use at 6 months for patients with diabetes at high CV or renal risk, researchers reported.

Idorsia announced that the FDA has approved aprocitentan, its antihypertensive drug, for treatment of hypertension in combination with other drugs in patients whose BP is not adequately controlled on other drugs.

Non-alcoholic fatty liver disease is an independent risk factor for osteoarthritis, according to data published in Arthritis Research & Therapy.

The results of the second annual national primary care scorecard suggest the field is facing major problems — poor funding and a diminishing workforce, among them — but increased attention on the issues may offer hope, according to experts.

High weekly averages of moderate to vigorous physical activity, or MVPA, were associated with a reduced risk for progression to chronic kidney disease, according to researchers.

A 55-year-old man new to the area presents to the ED complaining of excruciating left flank pain that radiates into his scrotum. He noted blood in the urine this morning and became worried enough to seek emergency care.

Adding salt to food — even sometimes — was linked to an increased risk for chronic kidney disease, according to a study published in JAMA Network Open.

Elevated resting heart rate may be a novel risk factor for end-stage renal disease, independent from other traditional risk factors, according to a study published in the Journal of the American Heart Association.

SAN DIEGO — Patients with lupus who received sodium-glucose cotransporter-2 inhibitors demonstrated reduced risks for major adverse cardiovascular events and kidney disease, a speaker said at ACR Convergence 2023.

SAN DIEGO — Obinutuzumab use increases the chances of achieving complete renal response and lowers the risk for kidney-related events and time to flare in lupus nephritis, according to data presented at ACR Convergence 2023.